

BVT-0455

27-Aug-2015


Pyridomycin

[Antibiotic U 24544; Erizomycin; NSC 246134]

BVT-0455-M001	1 mg
BVT-0455-MM25	2.5 mg
Formula	C ₂₇ H ₃₂ N ₄ O ₈
MW	540.6
CAS	18791-21-4

Handling / Storage

Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	+4°C



Protect from light when in solution.

Use / Stability

Stable for at least 1 year after receipt when stored at +4°C.

MSDS available at www.adipogen.com or upon request.

Product Specifications

Source/Host	Isolated from <i>Streptomyces</i> sp.
Purity	≥98% (1H-NMR, HPLC)
Identity	Determined by ¹ H-NMR and MS.
Appearance	Off-white solid.
Solubility	Soluble in DMSO, methanol, water, dichloromethane or acetone.

Product Description

- Cyclodepsipeptide antibiotic. Unusual 12-membered macrocyclic depsipeptide comprises three unique sub-units incorporating two substituted pyridines.
- Potent antitubercular agent.
- Inhibitor of NADH-dependent enoyl (Acyl-Carrier-Protein) reductase InhA, preventing mycolic acid synthesis in *M. tuberculosis*.
- Shown to be active against isoniazid-resistant mycobacteria.

WARNING: Intended for research use only. This product is not intended or approved for human, diagnostics, therapeutic or veterinary use. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death. **MATERIAL SAFETY DATA:** Review the complete Material Safety Data Sheet before use.

BioViotica Naturstoffe GmbH
c/o Adipogen AG
Schützenstrasse 12
4410 Liestal - Switzerland
TEL +41-61-926-60-40
FAX +41-61-926-60-49
bioviotica@adipogen.com

BioViotica Naturstoffe GmbH
Dransfelder Weg 6
D-37127 Dransfeld
Germany
TEL +49-5502-30-00-08
info@bioviotica.com

For Local Distributors see

www.adipogen.com

Product Specific References

1. A new antibiotic, pyridomycin: K. Maeda, et al.; J. Antibiot. (Tokyo) **6**, 140 (1953)
2. Structure of pyridomycin: G. Koyama, et al.; Tetrahedron Lett. **37**, 3587 (1967)
3. Chemistry of pyridomycin: H. Ogawara, et al.; Chem. Pharm. Bull. **16**, 679 (1968)
4. Synthetic studies of pyridomycin. V. Total synthesis of pyridomycin: M. Kinoshita, et al.; Tetrahedron Lett. **30**, 7419 (1989)
5. Identification and characterization of the pyridomycin biosynthetic gene cluster of streptomyces pyridomyceticus NRRL B-2517: T. Huang, et al.; J. Biol. Chem. **286**, 20648 (2011)
6. Towards a new tuberculosis drug: pyridomycin - nature's isoniazid: R. C. Hartkoorn, et al.; EMBO Mol. Medicine **4**, 1032 (2012)
7. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA: R. C. Hartkoorn, et al.; Nat. Chem. Biol. **10**, 96 (2014)

WARNING: Intended for research use only. This product is not intended or approved for human, diagnostics, therapeutic or veterinary use. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death. **MATERIAL SAFETY DATA:** Review the complete Material Safety Data Sheet before use.

BioViotica Naturstoffe GmbH
c/o Adipogen AG
Schützenstrasse 12
4410 Liestal - Switzerland
TEL +41-61-926-60-40
FAX +41-61-926-60-49
bioviotica@adipogen.com

BioViotica Naturstoffe GmbH
Dransfelder Weg 6
D-37127 Dransfeld
Germany
TEL +49-5502-30-00-08
info@bioviotica.com

For Local Distributors see

www.adipogen.com